摩熵化学
数据开放平台 数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[(2,3-Dimethylphenyl)methyl]piperazine

中文名称
——
中文别名
——
英文名称
1-[(2,3-Dimethylphenyl)methyl]piperazine
英文别名
——
1-[(2,3-Dimethylphenyl)methyl]piperazine化学式
CAS
——
化学式
C13H20N2
mdl
——
分子量
204.31
InChiKey
AUYYHCNVODQPBL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    15.3
  • 氢给体数:
    1
  • 氢受体数:
    2

文献信息

  • Inhibitors of p38 kinase
    申请人:——
    公开号:US20030092717A1
    公开(公告)日:2003-05-15
    The invention is directed to methods to inhibit p38-&agr; kinase using compounds of the formula 1 and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein represents a single or double bond; B is —W i —COX j Y wherein Y is COR 2 or an isostere thereof and R 2 is hydrogen or a noninterfering substituent, each of W and X is a spacer of 2-6 Å, and each of i and j is independently 0 or 1; each R 3 is independently a noninterfering substituent, where n is 0-3; Z 3 is NR 7 or O; wherein R 7 is H or a noninterfering substituent; one Z 2 is CA or CR 8 A and the other is CR 1 , CR 1 2 , NR 6 or N wherein each R 1 , R 6 and R 8 is independently hydrogen or noninterfering substituent; wherein A is: 2 such that Z 1 is CR 5 or N wherein R 5 is hydrogen or a noninterfering substituent; each of 1 and k is an integer from 0-2 wherein the sum of 1 and k is 0-3; Ar is an aryl group substituted with 0-5 noninterfering substituents, wherein two noninterfering substituents can form a fused ring; each R 4 is independently a noninterfering substituent where m is 0-4; each of L 1 and L 2 is a linker; and the distance between the atom of Ar linked to L 2 and the center of the &bgr; ring is 4.5-24 Å.
    该发明涉及使用式1化合物及其药用盐来抑制p38-α激酶的方法,或者其药物组合物,其中表示单键或双键;B为—Wi—COXjY,其中Y为COR2或其同分异构体,R2为氢或非干扰基,W和X各自为2-6埃的间隔物,i和j各自独立为0或1;每个R3各自为非干扰基,其中n为0-3;Z3为NR7或O;其中R7为H或非干扰基;一个Z2为CA或CR8A,另一个为CR1、CR12、NR6或N,其中每个R1、R6和R8各自独立为氢或非干扰基;其中A为:2,使得Z1为CR5或N,其中R5为氢或非干扰基;每个1和k为0-2的整数,其中1和k的和为0-3;Ar为带有0-5个非干扰基的芳基,其中两个非干扰基可形成融合环;每个R4各自为非干扰基,其中m为0-4;每个L1和L2为连接物;以及与L2连接的Ar原子与β环中心之间的距离为4.5-24埃。
  • [EN] INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE<br/>[FR] DERIVES DE TYPE INDOLE EN TANT QU'INHIBITEURS DE p38 KINASE
    申请人:SCIOS INC
    公开号:WO2000071535A1
    公开(公告)日:2000-11-30
    The invention is directed to methods to inhibit p38-α kinase using compounds of formula (1), and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein (a) represents a single or double bond; one Z2 is CA or CR8A and the other is CR1, CR12, NR6 or N wherein each R?1, R6 and R8¿ is independently hydrogen or noninterfering substituent; A is -W¿i?-COXjY wherein Y is COR?2¿ or an isostere thereof and R2 is hydrogen or a noninterfering substituent, each of W and X is a spacer of 2-6Å, and each of i and j is independently 0 or 1; Z?3 is NR7¿ or O; each R3 is independently a noninterfering substituent; n is 0-3; each of L?1 and L2¿ is a linker; each R4 is independently a noninterfering substituent; m is 0-4; Z?1 is CR5¿ or N wherein R5 is hydrogen or a noninterfering substituent; each of l and k is an integer from 0-2 wherein the sum of l and k is 0-3; Ar is an aryl group substituted with 0-5 noninterfering substituents, wherein two noninterfering substituents can form a fused ring; and the distance between the atom of Ar linked to L2 and the center of the α ring is 4.5-24Å.
    该发明涉及使用式(1)的化合物及其药学上可接受的盐或药物组合物来抑制p38-α激酶的方法,其中(a)表示单个或双键;Z2中的一个为CA或CR8A,另一个为CR1、CR12、NR6或N,其中每个R?1、R6和R8¿都独立地表示氢或非干扰取代基;A为-W¿i?-COXjY,其中Y为COR?2¿或其同分异构体,R2为氢或非干扰取代基,W和X各自为2-6Å的间隔,i和j各自独立地为0或1;Z?3为NR7¿或O;每个R3都独立地表示非干扰取代基;n为0-3;每个L?1和L2¿都是一个连接基;每个R4都独立地表示非干扰取代基;m为0-4;Z?1为CR5¿或N,其中R5为氢或非干扰取代基;每个l和k都是0-2的整数,其中l和k的和为0-3;Ar是一个芳基基团,其被0-5个非干扰取代基取代,其中两个非干扰取代基可以形成融合环;并且与L2连接的Ar原子与α环中心的距离为4.5-24Å。
  • Indole-type derivatives as inhibitors of p38 kinase
    申请人:——
    公开号:US20030195355A1
    公开(公告)日:2003-10-16
    The invention is directed to methods to inhibit p38-&agr; kinase using compounds of the formula 1 and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein represents a single or double bond; one Z 2 is CA or CR 8 A and the other is CR 1 , CR 1 2 , NR 6 or N wherein each R 1 , R 6 and R 8 is independently hydrogen or noninterfering substituent; A is —W i —COX j Y wherein Y is COR 2 or an isostere thereof and R 2 is hydrogen or a noninterfering substituent, each of W and X is a spacer of 2-6 Å, and each of i and j is independently 0 or 1; Z 3 is NR 7 or O; each R 3 is independently a noninterfering substituent; n is 0-3; each of L 1 and L 2 is a linker; each R 4 is independently a noninterfering substituent; m is 0-4; Z 1 is CR 5 or N wherein R 5 is hydrogen or a noninterfering substituent; each of l and k is an integer from 0-2 wherein the sum of l and k is 0-3; Ar is an aryl group substituted with 0-5 noninterfering substituents, wherein two noninterfering substituents can form a fused ring; and the distance between the atom of Ar linked to L 2 and the center of the &agr; ring is 4.5-24 Å.
    该发明涉及使用公式1及其药学上可接受的盐或药物组合物来抑制p38-α激酶的方法,其中: 表示单键或双键; Z2中的一个为CA或CR8A,另一个为CR1、CR12、NR6或N,其中每个R1、R6和R8独立地为氢或非干扰基; A为—Wi—COXjY,其中Y为COR2或其等构体,R2为氢或非干扰基,W和X均为2-6 Å的间隔基,i和j各自独立地为0或1; Z3为NR7或O; 每个R3独立地为非干扰基; n为0-3; 每个L1和L2均为连接基; 每个R4独立地为非干扰基; m为0-4; Z1为CR5或N,其中R5为氢或非干扰基; l和k各自为0-2的整数,其中l和k的和为0-3; Ar为芳基基团,其上取代有0-5个非干扰基,其中两个非干扰基可以形成融合环; 与L2连接的Ar原子与α环中心之间的距离为4.5-24 Å。
  • Benzofuran derivatives as inhibitors of p38-alpha kinase
    申请人:——
    公开号:US20030158417A1
    公开(公告)日:2003-08-21
    The invention is directed to methods to inhibit p38-&agr; kinase using compounds of the formula 1 and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein represents a single or double bond; one Z 2 is CA or CR 8 A and the other is CR 1 , CR 1 2 , NR 6 or N wherein each R 1 , R 6 and R 8 is independently hydrogen or noninterfering substituent; A is —W i —COX j Y wherein Y is COR 2 or an isostere thereof and R 2 is hydrogen or a noninterfering substituent, each of W and X is a spacer of 2-6 Å, and each of i and j is independently 0 or 1; Z 3 is NR 7 or O; each R 3 is independently a noninterfering substituent; n is 0-3; each of L 1 and L 2 is a linker; each R 4 is independently a noninterfering substituent; m is 0-4; Z 1 is CR 5 or N wherein R 5 is hydrogen or a noninterfering substituent; each of l and k is an integer from 0-2 wherein the sum of l and k is 0-3; Ar is an aryl group substituted with 0-5 noninterfering substituents, wherein two noninterfering substituents can form a fused ring; and the distance between the atom of Ar linked to L 2 and the center of the &agr; ring is 4.5-24 Å.
    本发明涉及使用式1化合物及其药学上可接受的盐或制剂的方法,以抑制p38-α激酶,其中: - 表示单个或双键; - 其中一个Z2是CA或CR8A,另一个是CR1、CR12、NR6或N,其中每个R1、R6和R8独立地表示氢或非干扰取代基; - A是-Wi-COXjY,其中Y是COR2或其异构体,R2是氢或非干扰取代基,W和X分别是2-6埃的间隔基,i和j各自独立地为0或1; - Z3是NR7或O; - 每个R3独立地表示非干扰取代基; - n为0-3; - 每个L1和L2是连接基; - 每个R4独立地表示非干扰取代基; - m为0-4; - Z1是CR5或N,其中R5是氢或非干扰取代基; - 每个l和k是0-2的整数,其中l和k的和为0-3; - Ar是芳基基团,其上取代0-5个非干扰基团,其中两个非干扰基团可以形成融合环; - Ar与L2连接的原子与α环中心之间的距离为4.5-24埃。
  • Substituted bicyclic derivatives and use thereof
    申请人:Matsumoto Akiko
    公开号:US20090054401A1
    公开(公告)日:2009-02-26
    [Object] To provide a compound having prostaglandin production-suppressing action and leukotriene production-suppressing action. [Means for Solution] A compound represented by the formula (I): [In the formula, represents a single bond, or a double bond, Link represents a single bond, or a saturated or unsaturated straight hydrocarbon having 1 or 2 carbon atoms, W represents a single bond, oxygen atom, sulfur atom, N(Rw) etc., Rw represents hydrogen atom, an alkyl group having 1 to 8 carbon atoms etc, Rs represents -D-Rx etc., D represents a single bond, oxygen atom, sulfur atom etc., Rx represents a linear or branched saturated alkyl group having 3 to 8 carbon atoms etc., one of V 1 and V 2 represents Zx, and the other represents AR, Zx represents hydrogen atom, a linear or branched saturated alkyl group having 1 to 4 carbon atoms etc., AR represents a partially unsaturated or completely unsaturated condensed bicyclic carbon ring or heterocyclic ring, and Y represents hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms etc.], or a salt thereof.
    [目标] 提供一种具有前列腺素产生抑制作用和白三烯产生抑制作用的化合物。[解决方案] 一种由式(I)表示的化合物:[在式中,表示单键或双键,Link表示单键或具有1或2个碳原子的饱和或不饱和直链碳氢化合物,W表示单键、氧原子、原子、N(Rw)等,Rw表示氢原子、具有1至8个碳原子的烷基等,Rs表示-D-Rx等,D表示单键、氧原子、原子等,Rx表示具有3至8个碳原子的线性或支链饱和烷基等,V1和V2中的一个表示Zx,另一个表示AR,Zx表示氢原子、具有1至4个碳原子的线性或支链饱和烷基等,AR表示部分不饱和或完全不饱和的螺合环碳环或杂环,Y表示氢原子、具有1至4个碳原子的低烷基等。],或其盐。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫